TP53 mutations in breast — common in TNBC and basal-like; adverse prognostic. Not directl...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-MUT-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-EARLY-2024 SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | any pathogenic mutation OR del(17p) |
| Disease | DIS-BREAST |
| ESCAT tier | IIIB |
| Recommended combinations | per usual TNBC algorithm (KEYNOTE-522) |
| Evidence summary | TP53 mutations in breast — common in TNBC and basal-like; adverse prognostic. Not directly targeted; chemo / pembrolizumab (KEYNOTE-522) per usual TNBC algorithm. |
Notes
ESCAT IIIB. Gene-level cell — biallelic vs monoallelic distinction matters in MDS/AML (biallelic = TP53-multihit per IPSS-M / ICC 2022, far worse). Per-hotspot cells provided for the most common variants.
Used By
No reverse references found in the YAML corpus.